Autologous dendritic cell immunotherapy (DCVAC/PCa) added to docetaxel chemotherapy in a Phase III trial (viable) in men with advanced (mCRPC) prostate cancer. Issue 2 (December 2015) - Beer, Tomasz; Vogelzang, Nicholas; Bartůňková, Jiřina; Miller, Kurt; Oh, William; Oudard, Stephane; Pandha, Hardev; Sartor, A; Špíšek, Radek; Toole, Timothy; Borgstein, Niels; Gerritsen, Winald